Comparative Pharmacology
Head-to-head clinical analysis: TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TRAVASOL 2 75 SULFITE FREE W ELECTROLYTES IN DEXTROSE 5 IN PLASTIC CONTAINER versus TRAVASOL 4 25 IN DEXTROSE 20 IN PLASTIC CONTAINER.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% IN PLASTIC CONTAINER vs TRAVASOL 4.25% IN DEXTROSE 20% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
TRAVASOL 2.75% SULFITE FREE W/ ELECTROLYTES IN DEXTROSE 5% is a crystalline amino acid solution combined with electrolytes and dextrose. Amino acids provide substrates for protein synthesis, dextrose supplies calories to minimize protein catabolism, and electrolytes maintain acid-base and electrolyte balance.
Travasol 4.25% in Dextrose 20% is a parenteral nutrition solution providing amino acids and carbohydrates. Amino acids serve as substrates for protein synthesis, while dextrose supplies calories to prevent catabolism and promote anabolism. The solution corrects nitrogen balance and provides energy.
Intravenous infusion: 500-1000 mL administered over 1-2 hours per day, adjusted based on electrolyte and fluid requirements. Typical adult dose provides 2.75% amino acids and 5% dextrose with electrolytes.
Intravenous administration via central line. Typical adult dose: 500-1000 mL/day of TRAVASOL 4.25% in dextrose 20% (providing 4.25 g amino acids and 20 g dextrose per 100 mL) as part of total parenteral nutrition. Infusion rate: not to exceed 0.8 g/kg/h of amino acids. Individualize based on metabolic needs.
None Documented
None Documented
Amino acids: 15-30 min (rapid redistribution). Dextrose: 1-2 h. Clinical context: continuous infusion maintains steady state.
Not applicable; components are endogenous nutrients. Dextrose half-life <15 min in normal renal function; amino acids have variable half-lives (minutes) due to rapid metabolism and incorporation. Clinical context: continuous infusion maintains steady state.
Renal: >95% of infused amino acids and dextrose metabolites excreted as urea, CO2, and water. Biliary/fecal: negligible.
Renal excretion; amino acids are reabsorbed or metabolized, excess nitrogen excreted as urea (renal). Dextrose is metabolized to CO2 and water. No significant biliary/fecal elimination.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution